Key clinical point: Hyperkalemia is the most common adverse event associated with spironolactone usage in women, but is uncommon in women aged 45 years or younger.
Major finding: The most common adverse reaction in women taking spironolactone was hyperkalemia (16.1% all adverse events), but only 1.9% of all hyperkalemia events occurred in women aged 45 years or younger.
Study details: An analysis of 7,920 adverse events with spironolactone reported between Jan. 1, 1969, and Dec. 30, 2018, to the Food and Drug Administrative Adverse Event System Reporting Database.
Disclosures: The investigators reported that they had no conflicts of interest.
Wang Y, Lipner SR. Int J Womens Dermatol. 2020 May 18. doi: 10.1016/j.ijwd.2020.05.002.